| Literature DB >> 33800702 |
Nansi López-Valverde1, Bruno Macedo-de-Sousa2, Antonio López-Valverde1, Juan Manuel Ramírez3.
Abstract
Titanium (Ti) dental implant failure as a result of infection has been established at 40%, being regarded as one of the most habitual and untreatable problems. Current research is focused on the design of new surfaces that can generate long-lasting, infection-free osseointegration. The purpose of our study was to assess studies on Ti implants coated with different antibacterial surfaces, assessing their osseointegration. The PubMed, Web of Science and Scopus databases were electronically searched for in vivo studies up to December 2020, selecting six studies that met the inclusion criteria. The quality of the selected studies was assessed using the ARRIVE (Animal Research: Reporting of In Vivo Experiments) criteria and Systematic Review Center for Laboratory animal Experimentation's (SYRCLE's) risk of bias tool. Although all the included studies, proved greater osseointegration capacity of the different antibacterial surfaces studied, the methodological quality and experimental models used in some of them make it difficult to draw predictable conclusions. Because of the foregoing, we recommend caution when interpreting the results obtained.Entities:
Keywords: antibacterial coating surfaces; osseointegration; titanium dental implants
Year: 2021 PMID: 33800702 PMCID: PMC8066819 DOI: 10.3390/antibiotics10040360
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Figure 1Increase in publications in recent years, with the keywords “Ti dental implants” AND “antibacterial surfaces coating” Source: Web of Science.
Figure 2Flowchart.
Characteristics of included studies.
| Studies | Animal Model (n) | Location of Implant Placement | Follow-Up | Analysis Methods | Conclusions |
|---|---|---|---|---|---|
| Zhang et al. [ | Beagle dog model | Mandible (premolars and molar area) | 4 weeks |
Micro-CT. Bone volume (BV). Bone Mineral Density (BMD). Trabecular Thickness (Tb.Th). Trabecular Number (Tb.N). | The SLA-Ta (Tantalum) surface showed excellent antibacterial activity against |
| Zhou et al. [ | New Zealand rabbit model | Femoral shafts area | 8 weeks |
Histological analysis of the BIC. Pull-out force of the metallic Ti wires with and without coatings. Bacterial counting method | The incorporation of Strontium (Sr) induces a better osseointegration, but it did not affect its angiogenic and antibacterial capabilities. |
| Ding et al. [ | Wild mice model | The upper first right molar area | 8 weeks |
Micro-CT BIC Bone Area (BA) | The doxycycline (DC)-treated Hydroxyapatite (HA)-coated implant surface promotes bone apposition around the implant. |
| Nie et al. [ | Rat model | Femur | 3 weeks |
Micro-CT. BIC. | The bacitracin (BC) on the Ti surface demonstrated potential prophylaxis against Ti implant-associated infection. Further, the BC-coated Ti showed potential towards osteoinductvity in a rat model. |
| Lee et al. [ | Hound Labrador dogs | Mandibular premolar area | 8 weeks |
Radiographic recordings (Presence of a periimplant radiolucent zone). BIC BMD | Human bone morphogenetic protein- 2 (rhBMP-2)-coated tita- nium porous oxide implants induce significant bone formation. |
| Susin et al. [ | Hound Labrador dogs | Mandibular premolar area | 8 weeks |
Radiographic recordings (Presence of a periimplant radiolucent zone). BIC BMD | rhBMP-7 coated onto Ti porous-oxide surface implants induces clinically relevant local bone formation including osseointegration and vertical augmentation of the alveolar ridge. |
BV, bone volume; BMD, bone mineral density; Tb.Th, trabecular thickness; Tb.N, trabecular number; BIC, bone to implant contact; Ti, titanium; Ta, tantalum; Sr, strontium; BA, bone area; DC, doxycycline; BC, bacitracin; HA, hydroxyapatite; rhBMP, human bone morphogenetic protein.
Characteristics of implants.
| Studies | Implants | Implant Dimensions, D(Ø) × L (mm) | Ti Implant Shape | Antibacterial Surface Incorporation | Surface Coating |
|---|---|---|---|---|---|
| Zhang et al. [ | 24 | 3.3 Ø × L 10 | Screw | Tantalum (Ta) | The Ti base was sputtered Ti sprayed for 10 min. Then, Ta deposition was carried out for 40 min by sputtering. |
| Zhou et al. [ | 24 | 2.5 Ø × L 10 | Cylinder | Strontium (Sr) | The adhesion force and ion release of the coating are shown in figure. |
| Ding et al. [ | 20 | 0.8 Ø × L 1.5 | Screw | Doxycycline (DC) | Frequency sputtering method. |
| Nie et al. [ | 36 | 1.5 Ø ×L 20 | Rod | Bacitracin (BC) | BC grafted on the surface of Ti bacitracin (concentration 1 mg/mL). |
| Lee et al. [ | 72 | 4.3 Ø × 10 L | Screw | 30 µg rhBMPm-2/implant was applied. | Immersion of the entire implant in an rhBMP-2 solution. |
| Susin et al. [ | 36 | 4 Ø × 10 L | Screw | 30 µg rhBMPm-7/implant was applied. | Immersion of the entire implant in an rhBMP-7 solution. |
Ta, tantalum; Sr, strontium; DC, doxycycline; BC, bacitracin; rhBMP, human bone morphogenetic protein.
Antibacterial activity and bone formation in vivo. Outcomes.
| Studies, | Antibacterial Activity | Bone Formation |
|---|---|---|
| Zhang et al. [ | The SLA-Ta surface hampered the biofilm formation of | Better osseointegration of the Ta coating. |
| Zhou et al. [ | NR | The Sr coatings gave the implants better osseointegration ability compared to bare metal Ti substrates. |
| Ding et al. [ | NR | At 4 and 8 weeks, BIC of DC group, was significantly higher than the one of HA group. |
| Nie et al. [ | The number of bacteria in the bacitracin (BC) modified Ti implant was significantly lower compared to the unmodified Ti rod group. | BIC for the Ti–BC implants were |
| Lee et al. [ | NR |
The induced bone was thin trabecular bone, with restricted BIC. Lamellar bone formation in at implants with to localized rhBMP-2 coating. BD averaged 38.0 ± 3.8% and 34.4 ± 5.6% for coronal- and soak-load implants, respectively ( BIC-values averaged 25.0 ± 3.8% and 31.2 ± 3.3% ( |
| Susin et al. [ | NR | BIC values for Ti implants versus Ti coated with rhBMP-7 |
NR, not reported; BIC, bone implant contact; BD, bone density; Ta, tantalum; Sr, strontium; DC, doxycycline; BC, bacitracin; HA, hydroxyapatite.
Figure 4SYRCLE’s (Systematic Review Centre for Laboratory Animal Experimentation) risk of bias tool.
Checklist of ARRIVE criteria reported by the included studies.
| Studies | Zhang et al. [ | Zhou et al. [ | Ding et al. [ | Nie et al. [ | Lee et al. [ | Susin et al. [ |
|---|---|---|---|---|---|---|
| 1. Title | 1 | 1 | 1 | 1 | 1 | 1 |
| Abstract | ||||||
| 2. Species | 1 | 1 | 1 | 1 | 1 | 1 |
| 3. Key finding | 1 | 1 | 1 | 1 | 1 | 1 |
| Introduction | ||||||
| 4. Background | 1 | 1 | 1 | 1 | 1 | 1 |
| 5. Reasons for | 0 | 0 | 0 | 0 | 0 | 0 |
| 6. Objectives | 1 | 1 | 1 | 1 | 1 | 1 |
| Methods | ||||||
| 7. Ethical statement | 1 | 1 | 1 | 1 | 1 | 1 |
| 8. Study design | 1 | 1 | 1 | 1 | 1 | 1 |
| 9. Experimental | 1 | 1 | 1 | 1 | 1 | 1 |
| 10. Experimental | 1 | 1 | 1 | 1 | 1 | 1 |
| 11. Accommodation and | 0 | 1 | 0 | 1 | 0 | 0 |
| 12. Sample size | 1 | 1 | 1 | 1 | 1 | 1 |
| 13. Assignment of | 1 | 1 | 1 | 1 | 1 | 1 |
| 14. Anesthesia | 1 | 1 | 1 | 1 | 1 | 1 |
| 15. Statistical methods | 1 | 1 | 1 | 1 | 1 | 1 |
| Results | ||||||
| 16. Experimental results | 1 | 1 | 1 | 1 | 1 | 1 |
| 17. Results and | 1 | 1 | 1 | 1 | 1 | 1 |
| Discussion | ||||||
| 18. Interpretation | 1 | 1 | 1 | 1 | 1 | 1 |
| 19. 3Rs reported | 0 | 0 | 0 | 0 | 0 | 0 |
| 20. Adverse events | 0 | 0 | 0 | 0 | 0 | 0 |
| 21. Study limitations | 0 | 0 | 0 | 0 | 0 | 0 |
| 22. Generalization/ | 1 | 1 | 0 | 1 | 1 | 1 |
| 23. Funding | 0 | 0 | 0 | 1 | 1 | 1 |
| TOTAL, SCORE | 17 | 18 | 16 | 19 | 18 | 18 |
17.6 ± 1.03. Score and mean deviation of the studies included.